Diaceutics and Syndax expand Relay partnership

Summary by AI BETAClose X

Diaceutics PLC has expanded its multi-year Relay partnership with Syndax Pharmaceuticals, Inc. to support the commercialization of Syndax's precision oncology medicine for acute leukaemia. This expanded agreement aims to accelerate the identification and treatment of eligible patients by leveraging Diaceutics' integrated commercialization solutions, which encompass diagnostic regulatory planning, testing landscape analysis, and physician engagement. The partnership builds upon an existing agreement from Q4 2025 and underscores a shared commitment to improving patient outcomes through enhanced patient identification and commercial execution in the precision medicine space.

Disclaimer*

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings